---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-032533"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2025-08-25T23:59:59+00:00"
generated_at: "2026-05-17T10:09:35.605337+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics raises $3.5M in private placement led by board chair for gene therapy manufacturing

## Summary
- Issued 3,138,338 shares at ~$1.11/sh in private placement; gross proceeds $3.5M.
- Led by board chair Cam Gallagher ($1M) and lead independent director Sean Ainsworth.
- Proceeds to expedite manufacturing process development for gene therapy candidates OPGx-LCA5 and OPGx-BEST1.
- Private placement closed August 25, 2025; exempt under Section 4(a)(2) and Regulation D.

## SEC filing metadata
- accession: 0001140361-25-032533
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2025-08-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036125032533/0001140361-25-032533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036125032533/ef20054479_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-032533
- JSON: https://secwatch.observer/filing/0001140361-25-032533.json
- Plain text: https://secwatch.observer/filing/0001140361-25-032533.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.